Objectives: To examine the expression of the long coding RNA GSTM3TV2 in pancreatic cancer tissues and to examine its role and mechanism in chemoresistance of pancreatic cancer cells. Methods: The expression of lncRNA GSTM3TV2 in 15 pancreatic cancer specimens and corresponding adjacent to cancer tissue samples diagnosed by Department of Pathology, Peking Union Medical College Hospital was detected by real-time PCR.And the expressions of GSTM3TV2 in pancreatic cancer cell AsPC-1, BxPC-3, MIAPaCa-2, PanC-1, SU86.86, T3M4, and chemoresistant cells AsPC-1/GR and MIAPaCa-2/GR, and human pancreatic nestin-expressing cells hTERT-HPNE were detected. Pancreatic cancer cell lines were transfected with GSTM3TV2-pcDNA3.1(+)in order to get cells with GSTM3TV2 overexpression.GSTM3TV2-siRNA was transfected into pancreatic cancer cells to knock down GSTM3TV2. The cell chemoresistance was measured by CCK-8 and flow cytometry assay when incubated with nab-paclitaxel. At the same time, subcutaneous xenograft tumor models were established in nude mice to observe the effect of GSTM3TV2 on chemoresistance of tumor growth in nude mice.Western blot assay was also performed to detect the molecular mechanism of chemoresistance of GSTM3TV2. Results: Comparing toadjacent tissues(0.084±0.019), GSTM3TV2 expression was significantly upregulated in the pancreatic cancer tissues(0.493±0.084) (t=5.146, P<0.05). GSTM3TV2 expression were higher in the chemotherapy resistance pancreatic cancer cells AsPC-1/GR(210.799±19.788) and MIAPaCa-2/GR(122.408±23.419) than that in the AsPC-1(3.793±0.615) and the MIAPaCa-2(5.179±1.095)(t=21.800,P<0.05;t=-18.490,P<0.05). The results of in vivo experiments showed that the volume of subcutaneously transplanted tumors in the overexpressing GSTM3TV2 group ((1 059.609±102.498)mm(3)) was significantly larger than that in the control group((566.414±81.087) mm(3)) by treated with nab-paclitaxel(t=4.230,P<0.05).Meanwhile, GSTM3TV2 could promote the expression of Cyclin D1, CDK6, Cyclin E1, Vimentin, N-cadherin, ZEB1, Snail and Slug; but decrease cleaved caspase-3, cleaved PARP in pancreatic cancer cells. Conclusions: The expression level of GSTM3TV2 in pancreatic canceris higher than that in paired adjacent tissues. GSTM3TV2 may act as an oncogene to promote chemoresistance in pancreatic cancer through regulation of cell proliferation, apoptosis, and epithelial-mesenchymal transition.
目的: 探讨长链非编码RNA GSTM3TV2在胰腺癌中的表达及其对胰腺癌细胞化疗耐药的调控作用和可能机制。 方法: 收集2016年7—8月在北京协和医院基本外科接受手术治疗的15例胰腺导管腺癌患者的癌组织和其配对的癌旁组织,以及人胰腺癌细胞株AsPC-1、BxPC-3、MIAPaCa-2、PanC-1、SU86.86、T3M4、耐药株AsPC-1/GR、耐药株MIAPaCa-2/GR和人正常胰腺上皮细胞株hTERT-HPNE。采用实时定量PCR法检测GSTM3TV2在胰腺癌组织及细胞中表达情况。通过脂质体转染法使胰腺癌细胞中过表达或抑制表达GSTM3TV2后,采用CCK-8法和流式细胞仪检测GSTM3TV2对胰腺癌细胞化疗敏感性的影响。构建GSTM3TV2稳定过表达胰腺癌细胞株,建立裸鼠皮下移植瘤模型,在体内水平进一步观察GSTM3TV2对胰腺癌细胞化疗敏感性的影响。同时,采用免疫印迹法检测GSTM3TV2在胰腺癌细胞化疗耐药过程中可能的分子机制。 结果: GSTM3TV2在胰腺癌组织中的表达水平(0.493±0.084)高于癌旁组织(0.084±0.019)(t=5.146,P<0.05);同时,GSTM3TV2在胰腺癌耐药细胞株AsPC-1/GR(210.799±19.788)和MIAPaCa-2/GR(122.408±23.419)中的表达水平高于其亲本株(3.793±0.615和5.179±1.095)(t=21.800,P<0.05;t=-18.490,P<0.05)。体内实验结果提示,经化疗药物治疗后,稳定过表达GSTM3TV2的胰腺癌裸鼠皮下移植瘤的体积[(1 059.609±102.498)mm(3)]大于对照组[(566.414±81.087)mm(3)](t=4.230,P<0.05)。免疫印迹法检测结果显示,过表达GSTM3TV2可促进细胞增殖相关蛋白Cyclin D1、Cyclin E1、CDK6等的表达,抑制细胞凋亡相关蛋白cleaved caspase-3、cleaved PARP等的表达可增加上皮间质转化相关蛋白Vimentin、N-cadherin、ZEB1、Snail及Slug等表达;反之则抑制GSTM3TV2的表达水平。 结论: 长链非编码RNA GSTM3TV2在胰腺癌组织中呈高表达,可降低胰腺癌细胞的化疗敏感性,其调控化疗耐药的机制可能与胰腺癌细胞增殖、凋亡及上皮间质转化信号转导通路的异常活化相关。.
Keywords: Drug resistance, neoplasm; GSTM3TV2; Long non-coding RNA; Pancreatic neoplasms.